<p>箭頭製藥（NASDAQ:ARWR - 獲取免費報告）在週五向投資者發佈的報告中，被華爾街 Zen 的股票研究人員從 “持有” 評級上調至 “買入” 評級。</p>
<ul>
<li>想要在生物技術領域獲得多元化的上行潛力？查看 LABU</li>
</ul>
<p>其他股票研究分析師最近也對該公司發佈了報告。花旗集團將箭頭製藥的目標價格從 21.00 美元下調至 17.00 美元，並在 5 月 13 日的報告中對該股票給予 “中性” 評級。HC Wainwright 在 5 月 20 日的研究報告中重申了 “買入” 評級，並對箭頭製藥的股票設定了 80.00 美元的目標價格。B. Riley 在 2 月 14 日的研究報告中重申了 “買入” 評級，並將箭頭製藥的股票目標價格設定為 38.00 美元（之前為 51.00 美元）。加拿大皇家銀行在 2 月 11 日的研究報告中重申了 “跑贏大盤” 評級，並將箭頭製藥的股票目標價格設定為 42.00 美元。最後，Chardan Capital 在 5 月 13 日的研究報告中重申了 “買入” 評級，並將箭頭製藥的股票目標價格設定為 60.00 美元。兩位股票研究分析師對該股票給予了持有評級，七位分析師對該公司的股票給予了買入評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，平均目標價格為 43.71 美元。</p>
<p><strong>閲讀我們關於 ARWR 的最新研究報告</strong></p>
<h2>箭頭製藥上漲 2.1%</h2>
<p>在週五的交易時段，NASDAQ ARWR 上漲 0.35 美元，達到 16.81 美元。該公司股票的交易量為 1,235,465 股，而其平均交易量為 1,523,956 股。該公司的 50 日移動平均線為 13.72 美元，200 日移動平均線為 17.35 美元。箭頭製藥的 12 個月低點為 9.57 美元，12 個月高點為 30.41 美元。該公司的市值為 23.2 億美元，市盈率為-3.25，貝塔值為 0.96。該公司的債務與股本比率為 7.27，速動比率為 6.09，流動比率為 6.09。</p>
<p>箭頭製藥（NASDAQ:ARWR - 獲取免費報告）最近於 5 月 12 日發佈了季度財報。這家生物技術公司報告的季度每股收益為 2.75 美元，超出分析師一致預期的（0.06 美元）2.81 美元。該公司在本季度的收入為 5.4271 億美元，而分析師預期為 1.1627 億美元。去年同期，該公司每股收益為（1.02 美元）。分析師預計箭頭製藥在當前財政年度將發佈-2.42 美元的每股收益。</p>
<h2>內部買賣</h2>
<p>在其他消息中，首席執行官 Christopher Richard Anzalone 在 4 月 9 日的交易中出售了 40,322 股公司的股票。該股票的平均售價為 10.07 美元，總交易額為 406,042.54 美元。出售完成後，首席執行官現在直接持有 4,022,055 股公司的股票，價值 40,502,093.85 美元。這代表着他們持有的股票減少了 0.99%。該出售在向 SEC 提交的文件中披露，文件可在 SEC 網站上獲取。內部人士在過去三個月內出售了 142,547 股公司股票，價值 1,764,709 美元。當前 4.30% 的股票由內部人士持有。</p>
<h2>機構投資者對箭頭製藥的看法</h2>
<p>對沖基金最近調整了對該股票的持有。Raymond James Financial Inc.在第四季度購買了價值 651,000 美元的箭頭製藥新股份。法國巴黎銀行金融市場在第四季度將其在箭頭製藥的持股增加了 59.5%。法國巴黎銀行金融市場目前持有 88,029 股生物技術公司的股票，價值 1,655,000 美元，此前在上個季度購買了 32,841 股。Empowered Funds LLC 在第四季度獲得了箭頭製藥的新頭寸，價值 268,000 美元。Slate Path Capital LP 在第四季度將其在箭頭製藥的持股增加了 7.1%。Slate Path Capital LP 目前持有 5,232,000 股生物技術公司的股票，價值 98,362,000 美元，此前在該期間購買了 347,000 股。最後，KLP Kapitalforvaltning AS 在第四季度獲得了箭頭製藥的新頭寸，價值 434,000 美元。62.61% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>箭頭製藥公司簡介</h2>
<p>（獲取免費報告）</p>
<p>箭頭製藥公司在美國開發用於治療難治性疾病的藥物。該公司的產品管線包括 Plozasiran，目前正在進行 2b 期和一項 3 期臨牀試驗，以治療高甘油三酯血癥、混合性血脂異常和乳糜微粒血癥；Zodasiran 正在進行 2b 期臨牀試驗，以治療血脂異常和高甘油三酯血癥；ARO-PNPLA3 正在進行 1 期臨牀試驗，以治療非酒精性脂肪性肝炎患者；ARO-RAGE 正在進行 1/2a 期臨牀試驗，以治療炎症性肺部疾病；ARO-MUC5AC 正在進行 1/2a 期臨牀試驗，以治療粘液阻塞性肺病。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票比箭頭製藥更好</li>
<li>如何在購買前評估一隻股票</li>
<li>大規模的石油供應減少可能意味着這三隻能源股票的上行潛力</li>
<li>三隻國防股票將受益於軍事支出的增加</li>
<li>三隻股票獲得分析師罕見的雙重升級</li>
<li>如何從成長投資中獲利</li>
<li>這家銀行巨頭剛剛獲得了 90 美元的目標價格上調</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在箭頭製藥嗎？</h2>
<p>在考慮箭頭製藥之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而箭頭製藥並不在名單上。</p>
<p>雖然箭頭製藥目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

箭頭制藥

<p>華爾街禪將箭頭製藥（NASDAQ:ARWR）的評級從 “持有” 上調至 “買入”。花旗集團將其目標價從 21.00 美元下調至 17.00 美元，維持 “中性” 評級。其他分析師，包括 HC Wainwright 和 B. Riley，重申了 “買入” 評級，目標價分別為 80.00 美元和 38.00 美元。該股上漲 2.1%，報 16.81 美元，平均評級為 “適度買入”，目標價為 43.71 美元。箭頭製藥報告的每股收益為 2.75 美元，超出預期，上一季度的收入為 5.4271 億美元</p>

<p>Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a note issued to investors on Friday.</p>
<div class="lb-trans"><p>箭頭製藥（NASDAQ:ARWR - 獲取免費報告）在週五向投資者發佈的報告中，被華爾街 Zen 的股票研究人員從 “持有” 評級上調至 “買入” 評級。</p>
</div><ul>
<li>Want Diversified Upside in Biotechnology? Check out LABU</li>
</ul>
<div class="lb-trans"><ul>
<li>想要在生物技術領域獲得多元化的上行潛力？查看 LABU</li>
</ul>
</div><p>Other equities research analysts also recently issued reports about the company. Citigroup dropped their target price on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a &#34;neutral&#34; rating on the stock in a report on Tuesday, May 13th. HC Wainwright reiterated a &#34;buy&#34; rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 20th. B. Riley restated a &#34;buy&#34; rating and set a $38.00 price objective (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. Royal Bank of Canada restated an &#34;outperform&#34; rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Finally, Chardan Capital reaffirmed a &#34;buy&#34; rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $43.71.</p>
<div class="lb-trans"><p>其他股票研究分析師最近也對該公司發佈了報告。花旗集團將箭頭製藥的目標價格從 21.00 美元下調至 17.00 美元，並在 5 月 13 日的報告中對該股票給予 “中性” 評級。HC Wainwright 在 5 月 20 日的研究報告中重申了 “買入” 評級，並對箭頭製藥的股票設定了 80.00 美元的目標價格。B. Riley 在 2 月 14 日的研究報告中重申了 “買入” 評級，並將箭頭製藥的股票目標價格設定為 38.00 美元（之前為 51.00 美元）。加拿大皇家銀行在 2 月 11 日的研究報告中重申了 “跑贏大盤” 評級，並將箭頭製藥的股票目標價格設定為 42.00 美元。最後，Chardan Capital 在 5 月 13 日的研究報告中重申了 “買入” 評級，並將箭頭製藥的股票目標價格設定為 60.00 美元。兩位股票研究分析師對該股票給予了持有評級，七位分析師對該公司的股票給予了買入評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，平均目標價格為 43.71 美元。</p>
</div><p><strong>Read Our Latest Research Report on ARWR</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 ARWR 的最新研究報告</strong></p>
</div><h2>Arrowhead Pharmaceuticals Trading Up 2.1%</h2>
<div class="lb-trans"><h2>箭頭製藥上漲 2.1%</h2>
</div><p>NASDAQ ARWR traded up $0.35 during trading hours on Friday, hitting $16.81. 1,235,465 shares of the company's stock were exchanged, compared to its average volume of 1,523,956. The business's 50 day moving average is $13.72 and its 200-day moving average is $17.35. Arrowhead Pharmaceuticals has a 12-month low of $9.57 and a 12-month high of $30.41. The firm has a market capitalization of $2.32 billion, a P/E ratio of -3.25 and a beta of 0.96. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09.</p>
<div class="lb-trans"><p>在週五的交易時段，NASDAQ ARWR 上漲 0.35 美元，達到 16.81 美元。該公司股票的交易量為 1,235,465 股，而其平均交易量為 1,523,956 股。該公司的 50 日移動平均線為 13.72 美元，200 日移動平均線為 17.35 美元。箭頭製藥的 12 個月低點為 9.57 美元，12 個月高點為 30.41 美元。該公司的市值為 23.2 億美元，市盈率為-3.25，貝塔值為 0.96。該公司的債務與股本比率為 7.27，速動比率為 6.09，流動比率為 6.09。</p>
</div><p>Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported $2.75 EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $2.81. The firm had revenue of $542.71 million during the quarter, compared to analysts' expectations of $116.27 million. During the same quarter last year, the business earned ($1.02) earnings per share. As a group, analysts anticipate that Arrowhead Pharmaceuticals will post -2.42 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>箭頭製藥（NASDAQ:ARWR - 獲取免費報告）最近於 5 月 12 日發佈了季度財報。這家生物技術公司報告的季度每股收益為 2.75 美元，超出分析師一致預期的（0.06 美元）2.81 美元。該公司在本季度的收入為 5.4271 億美元，而分析師預期為 1.1627 億美元。去年同期，該公司每股收益為（1.02 美元）。分析師預計箭頭製藥在當前財政年度將發佈-2.42 美元的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><p>In other news, CEO Christopher Richard Anzalone sold 40,322 shares of the company's stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $10.07, for a total transaction of $406,042.54. Following the completion of the sale, the chief executive officer now directly owns 4,022,055 shares of the company's stock, valued at $40,502,093.85. This represents a 0.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold 142,547 shares of company stock worth $1,764,709 in the last three months. 4.30% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他消息中，首席執行官 Christopher Richard Anzalone 在 4 月 9 日的交易中出售了 40,322 股公司的股票。該股票的平均售價為 10.07 美元，總交易額為 406,042.54 美元。出售完成後，首席執行官現在直接持有 4,022,055 股公司的股票，價值 40,502,093.85 美元。這代表着他們持有的股票減少了 0.99%。該出售在向 SEC 提交的文件中披露，文件可在 SEC 網站上獲取。內部人士在過去三個月內出售了 142,547 股公司股票，價值 1,764,709 美元。當前 4.30% 的股票由內部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Arrowhead Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對箭頭製藥的看法</h2>
</div><p>Hedge funds have recently modified their holdings of the stock. Raymond James Financial Inc. purchased a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at $651,000. BNP Paribas Financial Markets lifted its holdings in shares of Arrowhead Pharmaceuticals by 59.5% during the fourth quarter. BNP Paribas Financial Markets now owns 88,029 shares of the biotechnology company's stock valued at $1,655,000 after purchasing an additional 32,841 shares during the last quarter. Empowered Funds LLC acquired a new position in Arrowhead Pharmaceuticals during the fourth quarter valued at $268,000. Slate Path Capital LP raised its position in Arrowhead Pharmaceuticals by 7.1% during the fourth quarter. Slate Path Capital LP now owns 5,232,000 shares of the biotechnology company's stock valued at $98,362,000 after buying an additional 347,000 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new position in Arrowhead Pharmaceuticals during the fourth quarter valued at $434,000. 62.61% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>對沖基金最近調整了對該股票的持有。Raymond James Financial Inc.在第四季度購買了價值 651,000 美元的箭頭製藥新股份。法國巴黎銀行金融市場在第四季度將其在箭頭製藥的持股增加了 59.5%。法國巴黎銀行金融市場目前持有 88,029 股生物技術公司的股票，價值 1,655,000 美元，此前在上個季度購買了 32,841 股。Empowered Funds LLC 在第四季度獲得了箭頭製藥的新頭寸，價值 268,000 美元。Slate Path Capital LP 在第四季度將其在箭頭製藥的持股增加了 7.1%。Slate Path Capital LP 目前持有 5,232,000 股生物技術公司的股票，價值 98,362,000 美元，此前在該期間購買了 347,000 股。最後，KLP Kapitalforvaltning AS 在第四季度獲得了箭頭製藥的新頭寸，價值 434,000 美元。62.61% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Arrowhead Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>箭頭製藥公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.</p>
<div class="lb-trans"><p>箭頭製藥公司在美國開發用於治療難治性疾病的藥物。該公司的產品管線包括 Plozasiran，目前正在進行 2b 期和一項 3 期臨牀試驗，以治療高甘油三酯血癥、混合性血脂異常和乳糜微粒血癥；Zodasiran 正在進行 2b 期臨牀試驗，以治療血脂異常和高甘油三酯血癥；ARO-PNPLA3 正在進行 1 期臨牀試驗，以治療非酒精性脂肪性肝炎患者；ARO-RAGE 正在進行 1/2a 期臨牀試驗，以治療炎症性肺部疾病；ARO-MUC5AC 正在進行 1/2a 期臨牀試驗，以治療粘液阻塞性肺病。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Arrowhead Pharmaceuticals</li>
<li>How to Evaluate a Stock Before Buying</li>
<li>A Large Oil Supply Draw Could Mean Upside in These 3 Energy Names</li>
<li>3 Defense Stocks Set to Benefit From Increased Military Spending</li>
<li>3 Stocks Getting Rare Double Upgrades From Analysts</li>
<li>How to Profit From Growth Investing</li>
<li>This Banking Giant Just Got a $90 Price Target Upgrade</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比箭頭製藥更好</li>
<li>如何在購買前評估一隻股票</li>
<li>大規模的石油供應減少可能意味着這三隻能源股票的上行潛力</li>
<li>三隻國防股票將受益於軍事支出的增加</li>
<li>三隻股票獲得分析師罕見的雙重升級</li>
<li>如何從成長投資中獲利</li>
<li>這家銀行巨頭剛剛獲得了 90 美元的目標價格上調</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ARWR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Arrowhead Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在箭頭製藥嗎？</h2>
</div><p>Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮箭頭製藥之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而箭頭製藥並不在名單上。</p>
</div><p>While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然箭頭製藥目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

箭頭製藥（NASDAQ:ARWR）被華爾街 Zen 升級為買入評級